Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ant15, s usual you are correct. PYC have worked with Merck & co in 2014.
https://www.physiomics.co.uk/disclosure-of-large-pharma-partner-merck-co/
Laura, sorry for doubting your acumen.
Thankyou Ant
This was for yesterday
It's Day 2 of #Immuno2024! 🎉 Come chat with us about how our PKPD & QSP modelling expertise can inform and de-risk the development of the next generation of IO drugs. Contact hclose@physiomics.co.uk.
DB I think you will find the at PYC has contracted with both. I am open to correction but I believe I'm right. Thanks for all the excellent posts from yourself Laura, Trench et al . We will need some further buy pressure to move up But PYC can and will deliver this with News flow no doubt. Rather bust at present but will revert. Ant
Thanks Trench and Hopist
Good to see it holding above 1.32p support. Nice bull flag forming plus 50 & 200DMA both rising. The beginning of a Golden Cross set-up is visible. Just need a little bit more liquidity!!
GLA
The following report suggests that pressures on European cancer treatment are likely to grow significantly with 40% of specialist oncologists predicted to retire/leave over the next 5 years
https://www.rcr.ac.uk/media/hplj0uth/rcr-census_clinical-oncology-workforce-census_2022.pdf
'The need for novel oral cancer drugs, take at home and in the community, will only grow as hospital systems become more overloaded, and the numbers of specialist oncologists continues to decrease'
Must be some real opportunities here for PYC
Apologies and thankyou
Laura.
That is great. However, this is not the "Merck" client that uses PYC.
The "Merck" that uses PYC is Merck KGaA (Merck group)
The "Merck" in the news feed is Merck & co.
Let’s see if this Friday follows suit from the past few with a increase in volume and up tick in SP
Personalised !!
Perdpmaldoed medicines/vaccines /drugs are becoming more amd lore sought after which should help PYC
https://www.bbc.co.uk/news/health-68897731
An important trial of the world's first "personalised" mRNA vaccine against the deadliest form of skin cancer - melanoma - is now under way in the UK.
Steve Young, 52, from Stevenage, Herts, who had a melanoma growth cut out of his scalp last August, is one of the first patients to try the shot.
It is designed to help his immune system recognise and wipe out any remaining cancerous cells.
And hopefully, that means his cancer will not return.
The jab, mRNA-4157 (V940), uses the same technology as current Covid vaccines and is being tested in final-stage Phase III trials.
University College London Hospitals (UCLH) doctors are giving it alongside another drug, pembrolizumab or Keytruda, that also helps the immune system kill cancer cells.
Genetic signature
The combined treatment, made by Moderna and Merck Sharp and Dohme (MSD), is not yet available routinely on the NHS, outside of clinical trials.
Experts in some other countries, including Australia, are also trying it on patients, to gather more evidence and see whether it should be rolled out more widely.
The vaccine is personalised - meaning the make-up of it is changed to suit the individual patient.
Let the traders get there few % that’s the market and that needs to be accepted.
The MC needs / will rerate and will be multiples of the current.
Some will gain a few % some will gain hundreds.
Is what it is….
Clearly sitting waiting too. A few buys immediately pounced on with a proportional amount of sells.
Laura it seems like a pretty illiquid stock. Not many sellers around, hence can only buy small amounts.
The words clearly not out there yet.
As ever it’s hard to buy - they will need to let it run at some point…. Better be sitting in 3’s before news
Because
For about 7 -10 day s you can only buy £2,000 or so and then once bought it often goes to negotiates trade to buy , this is counter intuitive for a marker maker who wants to make a "market "
So now it's moved to 1.6p ask price it will soon be hard to buy after 1 or 2 buys
I bought back in yesterday and topped up again earlier today. Didn't have a problem but not a huge amount I bought. Looks like it's on the rise. Lloyds are showing mid price of 1.55p.
Only 5 trades and being held back? How do you come to that conclusion?
Yeah being held back imo - any small purchase will move this. 200ma broken
Anyone else finding this ?
Good to see Physiomics among the companies listed in the report
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells.Â
Thanks NK
Pyc are at the forefront of huge change in drug approval amd testing using A.I and mathematics
They ar e due to hit £900k+revenues and a pipeline of £1.6mln (up 60% in 4mths )
PYC current valuation is ludicrous
Absolutely agree. The signs are all pointing towards an exciting upward movement. Bullish all the way